Category: Uncategorized

Neumentum Target Investment by GMH

 Q3, 2019 New Target Investment Snapshot

To our investors and syndicate allies,  

Global Medical Holdings has one company that we are proud to present.  The company is listed in detail below in this email and in the summary here:

Neumentum, Inc.:  Neumentum is a privately held life science company focused on non-opioid alternatives to address pain. Neumentum is currently preparing for its forthcoming phase 3 trials of a non-opioid, acute, post-operative pain medication that is being developed under a 505(b)(2) FDA designation.


Neumentum, Inc.

A Non-Opioid Pain Company.

GMH Funding Amount:

$400k Convertible Note Round

$25k Unit Minimum

Investment Closing Date: Sept. 30, 2019

Neumentum, Inc. is headquartered in Palo Alto, CA and is a privately held life science company focused on non-opioid alternatives to address pain.  Neumentum is currently preparing for its forthcoming phase 3 trials of a non-opioid, acute, post-operative pain medication that is being developed under a 505(b)(2) FDA designation.  The lead product is a novel reformulation of the well-known approved non-opioid drug Ketorolac (trade name: Toradol),  from a short-acting injectable drug to a pre-mixed bag which provides a continuous infusion for a full 24 hours, resulting in smooth pharmacokinetics and sustained pain relief, thereby reducing the need for opioid intervention.  With potency equivalent to morphine, Toradol is already the most widely used non-opiate pain medication available for moderate-to–severe acute pain, especially in the post-operative setting.   In 2017, there were approximately, 45 million doses of this drug administered in the US, which accounted for approximately 10% of the total analgesics used in post-operative pain. The use of this drug has seen tremendous growth in use in the last year (18% growth year over year), and this growth is anticipated to continue as healthcare providers increasingly seek to avoid prescribing opioids.

Neumentum’s formulation of Ketorolac seeks to address many shortfalls of existing products by eliminating peaks and valleys of traditional Ketorolac administration, resulting in pain relief that is not only opioid-sparing, but also NSAID-sparing. If achieved, these innovations in delivery would enable more efficient and cost-effective care as well as better pain management and patient outcomes.  It fits ideally into the growing desire of hospitals to reduce and if possible replace opioids, as well as the economic pressure to reduce hospital stay to 24 hours for many post-surgical patients.

This round of financing will allow the company to accelerate the PK/Bioavailability study for Toradol PMB (Pre Mixed Bag), support preparation for the phase 3 trials, and support on-going business development activity, including a potential major in-licensing opportunity.

The Company’s management team is led by R. Scott Shively, CEO, who has more than 25 years’ experience working in pain in many roles, including Head of Pfizer’s $7B commercial pain portfolio where he developed and grew the Lyrica franchise. Additionally, Mr. Shively was instrumental in the $1B acquisition of Nucynta from J&J, and its subsequent relaunch at Depomed. Mr. Shively is joined by Dr. Joseph Pergolizzi, Jr. as Executive Chairman. Dr. Pergolizzi is an internationally recognized expert in pain medicine and has served as a top development and regulatory consultant for branded analgesics such as Nucynta, Cymbalta and Butrans. In addition, he founded and runs NEMA Research, Inc., a specialty contract research organization. 

GMH is pleased to arrange a call or meeting and will be setting up Founder Presentation Dates for you with Neumentum’s management team to provide you with a better understanding of the company’s technology and development plans. Please RSVP to any of the following dates and times:

Tuesday Sept 10, 4 to 5PM (EST)

Thursday Sept 12, 6 to 7PM (EST)

Saturdays Sept 14th, 21st, 28th, 1 to 2PM (EST)

Tuesday Sept 17, 6:30 to 7:30PM

Thursday Sept 19, 6:30 to 7:30PM

Tuesday Sept 24, 6:30 to 7:30PM

Thank you for being a part of the GMH Network of Investors,

GMH Management Team

Betaliq, Inc., a GMH Target Investment.

 July, 2019 New Target Investment Snapshot

New Target Company Investment by GMH

To our investors and syndicate allies,  

For this months new target company, we have one company that we are proud to present.  The company is listed in detail below in this email and in the summary here:

Betaliq, Inc.:  Betaliq is developing ophthalmic ß-blockers for the treatment of glaucoma using EyeSol® SFA formulation technology.  Ophthalmicß blockers are a sizeable and growing market with very little competition or innovation.


New Target Company

Betaliq, inc

Leveraging their EyeSol technology for various ophthalmic indications.

GMH Funding Amount:

$240k Series A Preferred

$20k Unit Minimum

Betaliq, inc. is headquartered In New York City, NY and is a privately held biopharmaceutical company formed in partnership with Novaliq GmbH to leverage their EyeSol technology for various ophthalmic indications.

EyeSol is a water-free, preservative-free solution for drug delivery that lends itself to use in ophthalmic indications. The EyeSol platform provides a solution in which drugs can be delivered to the eye with smaller drop size, higher residual time in the eye, and without additional excipients that may otherwise sting or cause other systemic safety concerns.  Because of the advantages afforded by this technological innovation, Betaliq is developing Eyesol based formulations of the beta-blockers timolol and nebivolol for treatment of Glaucoma. Timolol is the most widely prescribed ophthalmic beta blocker.  Nebivolol is a powerful selective beta blocker that could not previously be formulated for the eye.  Management believes that Novaliq’s topical formulation will provide substantial safety and efficacy benefits over the water-based solutions that are currently available.

Beta-blockers are an attractive potential lead product for the EyeSol platform due to the large market, significant systemic safety concerns of the existing products, low competitive activity, and high potential for additional combination products in various ophthalmic indications. Beta-blockers also have a very well established regulatory pathway and clearly defined clinical endpoints, so the development risk is low compared to other ophthalmic categories.

It is estimated that a robust phase 2 trial to determine the safety and efficacy of these formulations can be conducted with $6mm and 18 months.

The EyeSol technology has strong intellectual property protection and is backed by nearly 90 granted and allowed patents around the technology and process that through 2039.

Collage Partners, a division of CIM Securities, LLC is syndicating up to $8mm of Series A Convertible Preferred Stock at a $15mm pre-money valuation and is working with Global Medical Holdings to close out this round with the final $240,000.  

Betaliq has been co-founded by Novaliq, GMBH and BLP Management, LLC. Novaliq GMBH is a European specialty pharmaceuticals company.  BLP Management LLC is a successful developer of a number of ophthalmic products headed by Barry Butler. Barry is an ophthalmic industry veteran with over eight exits in the ophthalmic space including AcSentient exit to Ista, Sirion Therapeutics exit to Alcon, Clermont Pharmaceuticals exit to Nephron, Phenylephrine exit to Valeant, Kurobe Pharmaceuticals exit to Perrigo, Revitalid exit to Osmotica, Eyenovia exit via an IPO (NASDAQ: EYEN), and his most recent exit of Oculos Clinial Research, a specialty-CRO focused on ophthalmic indications.

We will reach out after you have had a chance to review the enclosed materials. In the meantime, please feel free to contact the GMH team with any questions you may have.

Best regards,     

Global Medical Holdings |

Offices Lexington Kentucky & Cincinnati Ohio 

Copyright 2019 All Rights Reserved. 

859-492-8280 or 513-370-3698

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google